Trial stopped: Long-acting injectable highly effective in preventing HIV in women

Organisation: Position: Deadline Date: Location:

One of the most eagerly awaited HIV study findings, that of an injection every two months that can prevents HIV infection in women, became reality this week with the announcement that the HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA) had been stopped early as results showed CAB LA to be highly effective in preventing HIV acquisition, reports WHO News.

Researchers announced that long-acting cabotegravir injections were safe and 90% superior to the daily oral tenofovir/emtricitabine currently used for HIV prevention among women in sub-Saharan Africa. The trial was headed by Dr Sinead Delany-Moretlwe, a research professor at the University of the Witwatersrand.

This finding was made on 5 November during a planned interim review of the HPTN 084 study data by the independent Data and Safety Monitoring Board (DSMB).
Consequently, the DSMB recommended that the study sponsor – the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health – stop the blinded phase of the trial, which was originally designed to continue through 2022, and share the results.

Study Design

The HPTN 084 enrolled 3,223 women aged 18-45 years old who were at risk for acquiring HIV infection in 20 sites across seven countries in strong>sub-Saharan Africa (Botswana, Kenya, Malawi, eSwatini, Uganda, Zimbabwe and seven sites in South Africa).

The study randomized participants to one of two arms:

• Arm A – CAB LA (as an intramuscular injection every 8 weeks) and daily oral TDF/FTC placebo.

• Arm B – Daily oral TDF/FTC and intramuscular CAB LA placebo every 8 weeks.

Results

Thirty-eight women in the trial acquired HIV. Four were randomised to the long-acting cabotegravir arm and 34 were randomised to the daily, oral FTC/TDF arm. This translated to an HIV incidence rate of 0.21% (95% CI 0.06% – 0.54%) in the cabotegravir group and 1.79% (95% CI 1.24%-2.51%) in the FTC/TDF group. While both methods were highly effective at preventing HIV acquisition, long-acting cabotegravir was 89% (95% CI 68-96%) more effective than FTC/TDF. These results show that CAB LA is significantly more effective in preventing HIV acquisition than oral PrEP in an intention-to-treat analysis from this trial.

CAB LA and oral FTC/TDF were both well tolerated and most adverse events were mild or moderate in severity and largely balanced between both treatment arms. Injection site reactions were low in both groups, though higher in the CAB LA arm and gastrointestinal disorders and nausea were more common in the FTC/TDF arm. There were no discontinuations due to injection site reactions or injection intolerance in either arm of the study.

Implications of the results

Women in the countries where the trial was conducted and across East and southern Africa continue to experience high HIV incidence. More effective and acceptable HIV prevention choices for women are needed. While oral PrEP is highly effective in preventing HIV in women when taken as prescribed, some women find it difficult to take a daily tablet, and inconsistent use of oral PrEP reduces the prevention effect. A long-acting injectable formulation has the potential to improve the prevention effect without relying on adherence to a daily oral PrEP regimen, and to increase prevention choices and acceptability among women.

A long-acting PrEP product could offer a better choice for women at substantial HIV risk who either do not want to take or struggle with taking a daily tablet. These results do not contradict evidence showing that consistently using oral PrEP is highly effective as has been demonstrated in several trials. However, adhering to the daily dosing schedule is important. Even short lapses in taking oral PrEP can reduce the protection from HIV acquisition.

CAB LA availability

Now that the trial in women has been stopped, the participants will be informed of the trial results and CAB LA will be made available to them. Participants who were in the FTC/TDF arm will be offered CAB LA and participants in the CAB LA arm will be able to continue to receive it. Participants who do not want to receive CAB LA will be offered FTC/TDF  until the originally planned study end.

Before CAB LA becomes available to people outside the HPTN 084 study, the trial results will have to be fully reviewed and submitted to a stringent regulatory authority for approval. CAB LA and manufacturing capacity will have to be developed. There are also other safety and implementation issues that need to be considered prior to a broader roll-out. Safety studies in adolescents and among pregnant and breastfeeding women will be needed and open-label extension (OLE) studies will need to be considered to understand the most effective and acceptable implementation approaches.

Outstanding issues

• CAB LA for adolescent girls

As the study participants were all aged 18 years or older, a bridging study (HPTN084/01) has started to enrol adolescent girls. This will assess safety and acceptability in 50 adolescent girls  < 18 years at three sites. Additional information on delivery approaches and ways to support uptake and continuation could be gained through OLE studies.

• Safety during pregnancy and breastfeeding

When information was made available in May 2018 regarding Dolutegravir (DTG), which is an integrase inhibitor in the same class of drug as cabotegravir, that there was a possible association with foetal neural tube defects (NTDs) when taken periconceptually, a protocol amendment was made requiring all women enrolled in HPTN 084 to also take long-acting reversible contraceptives. Since this safety signal was raised in May 2018, recent data has noted a decline in the risk. As of July 2020, data show a non-significant difference in risk of NTDs with DTG at conception exposure compared with other ARVs. However, because of the protocol change very few women in HPTN 084 became pregnant while taking CAB-LA. Monitoring for adverse foetal and pregnancy outcomes will have to be done during OLEs.

• Real-world implementation issues

Where and how CAB LA—which requires an injection every eight weeks—could be delivered, implementation adjustments that may be needed in HIV prevention programmes and health systems, and acceptability issues, will all need to be evaluated and considered. Other implementation assessments are planned or underway.

• The pharmacokinetic tail—will this be a significant risk for drug resistance?

Injectable cabotegravir has a long half-life, which is why it provides long-acting (8 weeks) protection. It also has a long pharmacokinetic tail, meaning that there is detectable drug that remains in the body for months after an injection. These small amounts of drug may not be enough to protect against HIV infection and could result in development of drug resistant HIV following exposure during this time. It has been previously reported in the Phase II study (HPTN 077)ii that the median time to undetectable cabotegravir is longer in women at 66.3 weeks (range 17.7 to 182) when compared to 42.7 weeks (range 20.4 to 134) in men. It is not yet understood if this long pharmacokinetic tail will have any significant effect on drug resistance.

The current recommendation for the HPTN 084 trial participants who discontinue CAB LA is to take FTC/TDF  to ‘cover’ this tail with an oral regimen. This may not be feasible, desired, or necessary in real-world settings. The importance of covering the tail with oral PrEP and the risk of subsequent HIV drug resistance are issues that will have to be considered and monitored carefully in future OLE studies.

A similar study (HPTN 083) in HIV-uninfected cisgender men who have sex with men and transgender women who have sex with men, was also stopped early by its DSMB in May 2020, after it also demonstrated that CAB LA was highly effective in preventing HIV acquisition in this group. Final analysis demonstrated the superiority of CAB LA compared to FTC/TDF for PrEP in the HPTN 083 study population. The results from HPTN 084 now mean that CAB-LA has been shown to be highly effective across populations.

 

HPTN 084 Frequently Asked Questions

 

See also:

 

MedicalBrief Archives: HPTN 084 Study – The promise of an HIV prevention injection

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.